12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

rFVIIIFc: Additional Phase I/IIa data

Additional data from an open-label, crossover, dose escalation Phase I/IIa trial in 16 treatment-experienced patients with severe hemophilia A showed that 25-65 IU/kg doses of IV rFVIIIFc increased half-life by 1.7x vs. Advate octocog alfa. rFVIIIFc was well tolerated. Data were presented at...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >